HIV, Antiretroviral Therapies, and the Brain

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2010 Apr 29

PMID 20425562

Citations 44

Authors

Kevin J Liner 2nd

Michelle J Ro

Kevin R Robertson

Affiliations

Soon will be listed here.

Abstract

While combination antiretroviral therapy (CART) has decreased the incidence of HIV-associated dementia, the severest form of HIV-associated neurocognitive disorders (HAND), mild neurocognitive disorder and asymptomatic neurocognitive impairment continue to persist, and there is evidence that neurocognitive deficits present even in acute HIV infection. Recent studies demonstrate that CART regimens with higher central nervous system (CNS) penetration effectiveness ranks may improve neurocognitive functioning. Considering these factors, earlier treatment initiation may be considered to protect the CNS. The functional impact of HAND on daily activities should be monitored. Areas that need further research are potential neurotoxicity of antiretrovirals, the eradication of potential latent reservoirs in the brain, when to start treatment to protect the CNS, and the neurological impact of HIV on the CNS in acute infection.

Citing Articles

Influence of plasma exosomes from women living with HIV Stratified by HAND on monocyte subpopulations from healthy women without HIV.

Collazo B, Ortiz-Valentin L, Negron-Rodriguez C, Medina-Colon J, Cantres-Rosario Y, Rodriguez E J Neurovirol. 2025; .

PMID: 39885101 DOI: 10.1007/s13365-024-01240-9.

ISG15-LFA1 interactions in latent HIV clearance: mechanistic implications in designing antiviral therapies.

Koka P, Ramdass B Front Cell Dev Biol. 2025; 12():1497964.

PMID: 39810915 PMC: 11729345. DOI: 10.3389/fcell.2024.1497964.

LM11A-31, a modulator of p75 neurotrophin receptor, suppresses HIV-1 replication and inflammatory response in macrophages.

Mirzahosseini G, Sinha N, Zhou L, Godse S, Kodidela S, Singh U Exp Biol Med (Maywood). 2024; 249:10123.

PMID: 39119118 PMC: 11306025. DOI: 10.3389/ebm.2024.10123.

Perinatal exposure to atazanavir-based antiretroviral regimens in a mouse model leads to differential long-term motor and cognitive deficits dependent on the NRTI backbone.

Dhume S, Balogun K, Sarkar A, Acosta S, Mount H, Cahill L Front Mol Neurosci. 2024; 17:1376681.

PMID: 38646101 PMC: 11027900. DOI: 10.3389/fnmol.2024.1376681.

HIV-Proteins-Associated CNS Neurotoxicity, Their Mediators, and Alternative Treatments.

Saro A, Gao Z, Kambey P, Pielnaa P, Marcellin D, Luo A Cell Mol Neurobiol. 2021; 42(8):2553-2569.

PMID: 34562223 PMC: 11421612. DOI: 10.1007/s10571-021-01151-x.

References

Woods S, Iudicello J, Moran L, Carey C, Dawson M, Grant I . HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychology. 2008; 22(1):110-7. PMC: 2249562. DOI: 10.1037/0894-4105.22.1.110. View

Marra C, Zhao Y, Clifford D, Letendre S, Evans S, Henry K . Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009; 23(11):1359-66. PMC: 2706549. DOI: 10.1097/QAD.0b013e32832c4152. View

Antinori A, Arendt G, Becker J, Brew B, Byrd D, Cherner M . Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789-99. PMC: 4472366. DOI: 10.1212/01.WNL.0000287431.88658.8b. View

Alexaki A, Liu Y, Wigdahl B . Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res. 2008; 6(5):388-400. PMC: 2683678. DOI: 10.2174/157016208785861195. View

Tozzi V, Balestra P, Salvatori M, Vlassi C, Liuzzi G, Giancola M . Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009; 52(1):56-63. DOI: 10.1097/qai.0b013e3181af83d6. View

Schweinsburg B, Taylor M, Alhassoon O, Gonzalez R, Brown G, Ellis R . Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol. 2005; 11(4):356-64. DOI: 10.1080/13550280591002342. View

Chattopadhyay N, Zastre J, Wong H, Wu X, Bendayan R . Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res. 2008; 25(10):2262-71. DOI: 10.1007/s11095-008-9615-2. View

Morgan E, Woods S, Weber E, Dawson M, Carey C, Moran L . HIV-associated episodic memory impairment: evidence of a possible differential deficit in source memory for complex visual stimuli. J Neuropsychiatry Clin Neurosci. 2009; 21(2):189-98. PMC: 2774938. DOI: 10.1176/jnp.2009.21.2.189. View

Gorman A, Foley J, Ettenhofer M, Hinkin C, van Gorp W . Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev. 2009; 19(2):186-203. PMC: 2871666. DOI: 10.1007/s11065-009-9095-0. View

10.

Robertson K, Smurzynski M, Parsons T, Wu K, Bosch R, Wu J . The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007; 21(14):1915-21. DOI: 10.1097/QAD.0b013e32828e4e27. View

11.

Hubben G, Bishai D, Pechlivanoglou P, Cattelan A, Grisetti R, Facchin C . The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life. AIDS Care. 2008; 20(4):449-55. DOI: 10.1080/09540120701867107. View

12.

Dickinson L, Khoo S, Back D . Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res. 2009; 85(1):176-89. DOI: 10.1016/j.antiviral.2009.07.017. View

13.

Heaton R, Cysique L, Jin H, Shi C, Yu X, Letendre S . Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J Neurovirol. 2008; 14(6):536-49. PMC: 2889205. DOI: 10.1080/13550280802378880. View

14.

Yilmaz A, Gisslen M, Spudich S, Lee E, Jayewardene A, Aweeka F . Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One. 2009; 4(9):e6877. PMC: 2731205. DOI: 10.1371/journal.pone.0006877. View

15.

Gutierrez-Valencia A, Viciana P, Palacios R, Ruiz-Valderas R, Lozano F, Terron A . Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med. 2009; 151(3):149-56. DOI: 10.7326/0003-4819-151-3-200908040-00127. View

16.

Hammer S, Eron Jr J, Reiss P, Schooley R, Thompson M, Walmsley S . Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008; 300(5):555-70. DOI: 10.1001/jama.300.5.555. View

17.

Sacktor N, Nakasujja N, Skolasky R, Rezapour M, Robertson K, Musisi S . HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis. 2009; 49(5):780-6. PMC: 2941149. DOI: 10.1086/605284. View

18.

Kitahata M, Gange S, Abraham A, Merriman B, Saag M, Justice A . Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360(18):1815-26. PMC: 2854555. DOI: 10.1056/NEJMoa0807252. View

19.

Harrington P, Schnell G, Letendre S, Ritola K, Robertson K, Hall C . Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS. 2009; 23(8):907-15. PMC: 3089803. DOI: 10.1097/QAD.0b013e3283299129. View

20.

Villar del Saz S, Sued O, Falco V, Aguero F, Crespo M, Pumarola T . Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up. J Neurovirol. 2008; 14(6):474-9. DOI: 10.1080/13550280802195367. View